Department of Clinical Pharmacy, Kaiser Permanente Colorado, Aurora 2Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver.
Department of Clinical Pharmacy, Kaiser Permanente Colorado, Aurora.
JAMA Intern Med. 2014 Mar;174(3):409-16. doi: 10.1001/jamainternmed.2013.13957.
The effect of antibiotic coadministration on the international normalized ratio (INR) in a relatively stable, real-world warfarin population has not been adequately described. Case reports and studies of healthy volunteers do not account for the potential contribution of acute illness to INR variability.
To compare the risk of excessive anticoagulation among patients with stable warfarin therapy purchasing an antibiotic (antibiotic group) with the risk in patients purchasing a warfarin refill (stable controls) and patients with upper respiratory tract infection but not receiving an antibiotic (sick controls).
DESIGN, SETTING, AND PARTICIPANTS: A retrospective, longitudinal cohort study evaluated patients receiving warfarin between January 1, 2005, and March 31, 2011, at Kaiser Permanente Colorado, an integrated health care delivery system. Continuous data were expressed as mean (SD) or median (interquartile range). Multivariable logistic regression analysis was used to identify factors independently associated with a follow-up INR of 5.0 or more. A total of 5857 (48.8%), 5579 (46.5%), and 570 (4.7%) patients were included in the antibiotic, stable control, and sick control groups, respectively. Mean age was 68.3 years, and atrial fibrillation was the most common (44.4%) indication for anticoagulation.
Warfarin therapy with a medical visit for upper respiratory tract infection or coadministration of antibiotics.
Primary outcomes were the proportion of patients experiencing a follow-up INR of 5.0 or more and change between the last INR measured before the index date and the follow-up INR.
The proportion of patients experiencing an INR of 5.0 or more was 3.2%, 2.6%, and 1.2% for the antibiotic, sick, and stable groups, respectively (P < .001, antibiotic vs stable control group; P < .017, sick vs stable control group; P = .44, antibiotic vs sick control group). Cancer diagnosis, elevated baseline INR, and female sex predicted a follow-up INR of 5.0 or more. Among antibiotics, those interfering with warfarin metabolism posed the greatest risk for an INR of 5.0 or more.
Acute upper respiratory tract infection increases the risk of excessive anticoagulation independent of antibiotic use. Antibiotics also increase the risk; however, most patients with previously stable warfarin therapy will not experience clinically relevant increases in INR following antibiotic exposure or acute upper respiratory tract infection.
在相对稳定的华法林人群中,抗生素合并使用对国际标准化比值(INR)的影响尚未得到充分描述。病例报告和健康志愿者的研究不能说明急性疾病对 INR 变异性的潜在影响。
比较稳定华法林治疗患者购买抗生素(抗生素组)与购买华法林续药(稳定对照组)和患有上呼吸道感染但未使用抗生素(感染对照组)患者的过度抗凝风险。
设计、设置和参与者:一项回顾性、纵向队列研究评估了 2005 年 1 月 1 日至 2011 年 3 月 31 日期间在 Kaiser Permanente Colorado 接受华法林治疗的患者,该系统为一体化医疗服务提供系统。连续数据表示为平均值(标准差)或中位数(四分位距)。多变量逻辑回归分析用于确定与随访 INR 为 5.0 或更高相关的独立因素。共有 5857(48.8%)、5579(46.5%)和 570(4.7%)名患者分别纳入抗生素组、稳定对照组和感染对照组。平均年龄为 68.3 岁,最常见的抗凝指征是心房颤动(44.4%)。
华法林治疗并伴有上呼吸道感染就诊或合并使用抗生素。
主要结局是随访 INR 为 5.0 或更高的患者比例以及在指数日期之前最后一次 INR 测量值与随访 INR 之间的变化。
抗生素组、感染对照组和稳定对照组的 INR 为 5.0 或更高的患者比例分别为 3.2%、2.6%和 1.2%(P <.001,抗生素 vs 稳定对照组;P <.017,感染 vs 稳定对照组;P =.44,抗生素 vs 感染对照组)。癌症诊断、基线 INR 升高和女性性别预测了 INR 为 5.0 或更高。在抗生素中,干扰华法林代谢的抗生素对 INR 为 5.0 或更高的风险最大。
急性上呼吸道感染增加了过度抗凝的风险,与抗生素的使用无关。抗生素也会增加这种风险;然而,大多数先前稳定接受华法林治疗的患者在接触抗生素或急性上呼吸道感染后不会出现 INR 临床相关增加。